- 作者：Erdem Ergun ; Noé ; mi Maá ; r ; Siamak Ansari-Shahrezaei ; Barbara Wimpissinger ; Katharina Krepler ; Andreas Wedrich and Michael Stur
- 刊名：American Journal of Ophthalmology
- 出版年：2006
- 出版时间：July 2006
- 年：2006
- 卷：142
- 期：1
- 页码：10
- 全文大小：381 K
Purpose
To examine the efficacy of photodynamic therapy (PDT) with verteporfin and intravitreal triamcinolone acetonide in the treatment of neovascular age-related macular degeneration (AMD).Design
Retrospective, interventional case series.
Methods
Sixty eyes of 56 patients with neovascular AMD were treated with PDT with verteporfin followed by an intravitreal injection of 4 mg triamcinolone acetonide. The main outcome measures were visual acuity (VA), retreatment frequency with PDT (and triamcinolone), and frequency of side effects.
Results
Mean follow-up was 15.9 months (range 12 to 30 months, median 15 months). Twenty-three (38.3 % ) of 60 eyes had a stable result at 12 months’ follow-up (that is, loss/gain <three lines) and 34 (56.7 % ) of 60 had a loss of 3 lines or more. Three patients (5 % ) had an improvement of 3 lines or more. Lesion type, patient age, and lesion size had no influence on the outcome, but baseline VA had a statistically significant effect (P = .006). The median number of PDT–intravitreal triamcinolone acetonide treatments was one. One-third (20 of 60) of all eyes had an increase in intraocular pressure (IOP) that required therapy. There were no cases of endophthalmitis, but 13 patients (21.6 % ) developed severe cataract that required surgery.
Conclusions
The combination of PDT and intravitreal triamcinolone acetonide requires careful consideration as a treatment option for neovascular AMD. In our case series, this treatment combination did not prevent a considerable decrease in VA. The main benefit of this combination treatment was a low number of verteporfin treatments. Baseline VA was the main predictor of the final outcome.